Natera Inc

NTRA

Equity

ISIN US6323071042 / Valor 28447012

NASDAQ (2025-04-01)

USD 140.65-0.54%

Natera Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Natera Inc. is a pioneering company in the healthcare sector, specializing in the development and commercialization of cell-free DNA (cfDNA) testing technologies. With a focus on oncology, women's health, and organ health, Natera strives to integrate personalized genetic testing and diagnostics into routine medical care. This approach is aimed at facilitating early and more precise interventions, ultimately contributing to improved health outcomes and extended life spans. The company's innovative solutions are designed to support patients and healthcare providers by offering critical insights into various health conditions and treatment responses, thereby enhancing the effectiveness of medical care. Through its commitment to advancing cfDNA testing, Natera plays a crucial role in the evolving landscape of personalized medicine.

Summarized from source with an LLMView SourceSector: Technology

Revenue Growth

Natera Inc. reported total revenues of $439.8 million for the third quarter of 2024, marking a significant increase of 63.9% compared to $268.3 million in the same quarter of 2023. This growth was primarily driven by a 64.4% increase in product revenues.

Gross Margin Improvement

The company achieved a gross margin of 61.8% in Q3 2024, up from 45.1% in Q3 2023. This improvement was attributed to higher revenues and progress in reducing the cost of revenues associated with tests processed.

Test Volume Increase

In the third quarter of 2024, Natera processed approximately 775,800 tests, a 23.9% increase from the 626,000 tests processed in the third quarter of 2023. This includes a significant rise in oncology tests performed, which increased by 54.4% year-over-year.

Net Loss Reduction

Natera reported a net loss of $31.6 million, or ($0.26) per diluted share, for Q3 2024, compared to a net loss of $109.0 million, or ($0.95) per diluted share, in Q3 2023. This reduction in net loss reflects improved operational efficiencies and revenue growth.

Financial Outlook

For the full year 2024, Natera has raised its revenue guidance, now expecting total revenues between $1.61 billion and $1.64 billion. The company also anticipates a gross margin of 58% to 61% and a net cash inflow ranging from $50 million to $75 million.

Summarized from source with an LLMView Source

Key figures

51.3%1Y

228%3Y

434%5Y

Performance

43.9%1Y

63.8%3Y

66.7%5Y

Volatility